Novo Nordisk's Wegovy Pill Just Hit 3 Million Prescriptions. Is Wall Street Missing Something With This Beaten-Down Stock?

Novo Nordisk is gaining traction with its Wegovy pill, which has already reached 3 million prescriptions and could help reclaim share in the GLP-1 market from Eli Lilly. The stock is down 70% from 2024 highs, but the company trades at 10x earnings versus Eli Lilly’s 40x P/E and offers a 4.1% dividend yield. Near-term headwinds remain, including lower U.S. pricing and generic competition in India, with 2026 described as a transition year.

Analysis

The market is treating NVO like a broken innovator, but the setup is closer to a compressed optionality trade: near-term earnings are being reset by pricing and mix, while the new pill format expands the addressable funnel by reducing the single biggest behavioral barrier to adoption. The second-order effect is that oral therapy can convert a much larger population of “considerers” than injectables ever could, which should improve prescription velocity even if per-patient economics are lower. That makes volume the key variable, not margin, over the next 4-6 quarters.

LLY still has the superior moat in perceived efficacy, but that advantage matters less in the oral channel if persistence and convenience drive the majority of incremental share gains. The real competitive risk is not just LLY’s pill, but follow-on entrants and compounded/discount channels that can commoditize the lower-acuity segment first. If oral GLP-1 becomes the mass-market SKU, the industry could shift toward a razor-thin gross margin architecture where scale, distribution, and payer access matter more than clinical differentiation.

The contrarian miss is that a 10x multiple on a franchise with durable demand, high switching costs, and a 4%+ yield may already discount a severe but temporary earnings trough. The stock can rerate quickly if management shows two consecutive quarters of accelerating oral scripts and stabilizing U.S. pricing, because the market will then have to underwrite a higher long-term unit base. The risk is that 2026 guidance proves conservative for the wrong reasons: if price cuts and foreign generic pressure hit simultaneously while the oral launch saturates slower than expected, the bear case turns from “transition year” to multi-year de-rating.

From a positioning standpoint, this is more attractive as a relative-value long than an outright call, because the valuation gap versus LLY is extreme but can persist if Lilly maintains execution superiority. The best catalyst window is the next 1-2 earnings prints, when prescription momentum can be contrasted against guidance reset; until then, sentiment will likely remain skeptical and short interest can provide support if data keeps improving.

Key Decisions for Investors

• Long NVO / short LLY pair trade for 3-6 months: express mean reversion on valuation compression while limiting sector beta; target 20-30% spread upside if NVO oral script growth keeps outpacing expectations.
• Buy NVO common on 5-10% pullbacks with a 12-month horizon: attractive if the market continues pricing 2026 as a one-year earnings event rather than a durable volume reset; downside should be capped by dividend support.
• Sell cash-secured puts on NVO 6-9 months out at strikes 10-15% below spot: monetize elevated skepticism while positioning to own the stock at a lower effective multiple.
• Avoid chasing LLY here; prefer to wait for either a pullback or evidence that oral-channel share gains are not material, because the current multiple already embeds flawless execution.
• If NVO reports two sequential quarters of accelerating oral prescriptions, add to the long and consider closing the LLY short leg, as the re-rating could begin faster than consensus expects.